Cardiac Implantable Electronic Devices in Ischemic Cardiomyopathy - 17/03/25

Doi : 10.1016/j.hfc.2024.12.009

Yash Kamani, MD, MBA ^a, Graham Peigh, MD, MSc ^b, Nishant Verma, MD, MPH ^b, Jeremiah Wasserlauf, MD, MSc, FHRS ^c,^⁎
^a Division of Cardiology, Northwestern University, Feinberg School of Medicine, Arthur J. Rubloff Building, 420 East Superior Street, Chicago, IL 60611, USA
^b Division of Cardiac Electrophysiology, Northwestern Memorial Hospital, 251 East Huron Street Suite 8-300, Chicago, IL 60611, USA
^c Division of Cardiology, Endeavor Health/University of Chicago Pritzker School of Medicine, 2650 Ridge Avenue, Evanston, IL 60201, USA

^∗Corresponding author.

Résumé

This review discusses the range of device therapy for ischemic cardiomyopathy (ICM). This article will review the primary data supporting guideline indications for cardiac implantable electronic devices in patients with ICM, with a focus on primary/secondary prevention transvenous implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy, and subcutaneous/extravascular ICDs. In addition, this review discusses emerging device therapy for ICM including left bundle area pacing/defibrillation, cardiac contractility modulation and baroflex activation therapy. Device therapy for ICM continues to evolve to incorporate diverse modalities across the spectrum from prevention of sudden cardiac death to modifying cardiac remodeling and recovery.

Le texte complet de cet article est disponible en PDF.

Keywords : Coronary artery disease, Implantable cardioverter-defibrillator, Cardiac resynchronization therapy, Subcutaneous implantable cardioverter-defibrillator, Extravascular implantable cardioverter-defibrillator, Left bundle branch area pacing, Baroreflex therapy, Cardiac contractility modulation